|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Theragenics® Regains Compliance with NYSE Listing Standards
6/5/2009 9:55:20 AM
BUFORD, Ga.--(BUSINESS WIRE)--Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced it was notified by the New York Stock Exchange (the “NYSE”) that the Company is in compliance with the NYSE continued listing requirement pertaining to market capitalization and stockholders’ equity, as modified by the NYSE. This continued listing criterion, as modified, requires a company to maintain shareholders’ equity of at least $50 million if the company’s average market capitalization over a 30-day trading period is less than $50 million. Previously, the numeric thresholds in this requirement were $75 million. This modification is effective through October 31, 2009. The NYSE has stated that it anticipates a subsequent rule filing prior to October 31, 2009 to make this change a permanent continued listing standard. As of April 5, 2009, the completion of the Company’s most recent quarterly period, its stockholders’ equity totaled $74.9 million. As previously announced, Theragenics was notified by the NYSE on March 18, 2009 that it had fallen below compliance with the continued listing standards, as the Company’s stockholders’ equity, shareholders’ equity and market capitalization over 30 trading days was below $75 million.
|
|
|
|
|
|
|
|
|
|
|